In yesterday’s Wall Street session, Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) shares traded at $1.94, down -1.52% from the previous session.
As of this writing, 4 analysts cover Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $3.00, we find $8.00. Given the previous closing price of $1.97, this indicates a potential upside of 306.09 percent. LXRX stock price is now -23.68% away from the 50-day moving average and -17.19% away from the 200-day moving average. The market capitalization of the company currently stands at $479.59M.
There are 2 analysts who have given it a hold rating, whereas 2 have given it a buy rating. Brokers who have rated the stock have averaged $7.00 as their price target over the next twelve months.
With the price target of $3, Jefferies recently initiated with Hold rating for Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX).
In other news, COATS LONNEL, Chief Executive Officer bought 10,000 shares of the company’s stock on Jun 29. The stock was bought for $21,600 at an average price of $2.16. Upon completion of the transaction, the Chief Executive Officer now directly owns 814,359 shares in the company, valued at $1.58 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 26, Chief Executive Officer COATS LONNEL bought 10,000 shares of the business’s stock. A total of $21,792 was incurred on buying the stock at an average price of $2.18. This leaves the insider owning 804,359 shares of the company worth $1.56 million. Insiders disposed of 178,167 shares of company stock worth roughly $0.35 million over the past 1 year. A total of 0.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in LXRX stock. A new stake in Lexicon Pharmaceuticals Inc. shares was purchased by NATIXIS ADVISORS, L.P. during the first quarter worth $170,000. GSA CAPITAL PARTNERS LLP invested $135,000 in shares of LXRX during the first quarter. In the first quarter, QUBE RESEARCH & TECHNOLOGIES LTD acquired a new stake in Lexicon Pharmaceuticals Inc. valued at approximately $118,000. CAPTRUST FINANCIAL ADVISORS acquired a new stake in LXRX for approximately $90,000. VIRTU FINANCIAL LLC purchased a new stake in LXRX valued at around $42,000 in the second quarter. In total, there are 155 active investors with 82.30% ownership of the company’s stock.
Wednesday morning saw Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) opened at $1.9700. During the past 12 months, Lexicon Pharmaceuticals Inc. has had a low of $1.71 and a high of $3.79. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.40, and a quick ratio of 5.40. The fifty day moving average price for LXRX is $2.5236 and a two-hundred day moving average price translates $2.3402 for the stock.
The latest earnings results from Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.17, beating analysts’ expectations of -$0.18 by 0.01. This compares to -$0.16 EPS in the same period last year. The company reported revenue of $24000.0 for the quarter, compared to $37000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -35.14 percent. For the current quarter, analysts expect LXRX to generate $70k in revenue.
Lexicon Pharmaceuticals Inc.(LXRX) Company Profile
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
